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ABSTRACT
Probiotics are defined as “live microorganisms which when administered in adequate 
amounts confer a health benefit on the host”. In this doctoral dissertation, probiotic 
strains Saccharomyces boulardii CNCM I-745 and Lacticaseibacillus rhamnosus GG 
(LGG) were developed as next-generation probiotics.
The constructed S. boulardii strains, i.e., SAC4 based on the wild-type S. boulardii 
CNCM I-745 and SAC12 based on the URA3 auxotrophic derivative, secreted 
bacteriocin leucocin C, which showed inhibitory activity against the foodborne 
pathogen Listeria monocytogenes. Interestingly, the leucocin C secretion ability of S. 
boulardii SAC12 was stronger than that of SAC4. S. boulardii SAC4 killed L. 
monocytogenes effectively when cells of yeast and Listeria were incubated together 
without selection pressure, demonstrating the potential of cell mediated inhibition 
instead of using concentrated supernatant. Beer fermented with SAC12 was evaluated 
to be efficient in Listeria decontamination of chicken breast strips, with the maximum 
reduction of 2.2 log units from (1.8 0.3) × 105 CFU/g.
LGG is one of the most studied probiotic strains, and it has been commercially used as 
a probiotic supplement in dairy products. The challenge of using LGG in dairy products 
is that it cannot metabolize the lactose and casein of milk, thus causing its poor growth 
in milk. We aimed to abolish this deficiency of LGG by bacterial conjugation, a non-
GMO method. The dairy strain Lactococcus lactis NCDO 712 was used as donor, as it 
carries the plasmid pLP712 with the gene encoding the protease for casein degradation 
as well as the gene for lactose catabolism. In this study, a successful conjugation was 
done between L. lactis NCDO 712 and LGG. The plasmid pLP712 was conjugated into 
LGG, verified by plasmid-specific PCR and plasmid DNA isolation. The 
transconjugant L. rhamnosus LAB49 showed a clear ability of lactose utilization on 
indicator plate, in which lactose was the only carbon source. LAB49 was incubated in 
MRS, and all tested colonies (n= 80) lost their lactose-fermenting ability after 100 
generations. The proteolytic activity of LAB49 was analyzed by SDS-PAGE and it 
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showed that β-casein was fully digested in 4 h by LAB49 and NCDO 712 but not at all 
by LGG. The growth curve indicated that LAB49 grew well in milk, reaching stationary 
phase in 11 to 12 h after inoculation. These results collectively suggested that, L. 
rhamnosus LAB49, an upgraded food-grade and non-GMO derivative of LGG had been 
generated.
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TIIVISTELMÄ (abstract in Finnish)
Probiootit ovat eläviä mikrobeja, jotka riittävissä määrin syötyinä vaikuttavat 
terveyteen myönteisellä tavalla. Tässä väitöskirjatutkimuksessa kehitettiin terveyttä 
edistävistä Saccharomyces boulardii CNCM I-745 ja Lacticaseibacillus rhamnosus GG 
(LGG) mikrobikannoista ns. uuden sukupolven probiootteja.
S. boulardii CNCM I-745 on probioottinen hiivakanta, joka estää bakteerien haitallisia 
vaikutuksia suolistossa. Tässä työssä sekä S. boulardii CNCM I-745 villityyppi että 
auksotrofinen URA3 –mutantti saatiin erittämään leukosiini C –nimistä bakteriosiinia, 
joka on tehokas estämään patogeenisen Listeria monocytogenes –bakteerin kasvua. 
URA3-mutantti-pohjaisen SAC12-kannan havaittiin olevan tehokkaampi leukosiinin 
erittäjä kuin villityyppiin perustuvan SAC4-kannan. S. boulardii SAC4 –kanta tappoi 
Listeriaa tehokkaasti, kun Listeria- ja hiivasoluja inkuboitiin yhdessä. Tämä 
koejärjestely osoitti nimenomaan soluvälitteisen inhibition olevan tehokasta 
kasvatusliemen sijaan. S. boulardii SAC12 –kannalla valmistettiin olutta, jolla 
marinoitiin Listerialla kontaminoituja kananrintasuikaleita. Olutmarinadi vähensi 
tehokkaasti Listeria-määriä kananrintasuikaleissa.
LGG on maailman tutkituimpia probioottisia maitohappobakteerikantoja, ja sitä 
käytetään probioottisena lisänä monissa kaupallisissa maitopohjaisissa tuotteissa. LGG 
ei kuitenkaan hajota maitosokeri laktoosia eikä maitoproteiini kaseiinia, eikä se siksi 
pysty kasvamaan maidossa. Tässä työssä nämä puutteet korjattiin bakteerien 
konjugaation avulla, koska konjugaatiota pidetään ns. non-GMO -
geeninsiirtomenetelmänä. Laktoosin ja kaseiinin hajotukseen tarvittavat geenit saatiin 
juustohapatebakteeri Lactococcus lactis NCDO 712 –kannan pLP712-plasmidista. 
LGG ja L. lactis NCDO 712 saatiin konjugoitumaan, jolloin plasmidi pLP712 siirtyi 
laktokokista LGG:hen. DNA:n siirtyminen varmistettiin PCR:llä ja 
plasmidieristyksellä. Transkonjuganttikanta L. rhamnosus LAB49 hajotti laktoosia 
kasvatusmaljalla, jossa laktoosi oli ainoa hiilenlähde kasvulle. Kun LAB49-kantaa 
kasvatettiin 100 sukupolvea ilman laktoosin tuottamaa selektiopainetta, se menetti 
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laktoosinkäyttökykynsä, mikä johtui plasmidin pLP712 rakenteellisesta epävakaudesta. 
LAB49-kannan proteolyyttinen aktiivisuus varmistettiin SDS-PAGE-geelissä, mikä 
osoitti LAB49:n hajottavan kaseiinin täydellisesti neljässä tunnissa. Näiden LAB49-
kannan uusien ominaisuuksien vaikutus kykyyn kasvaa maidossa testattiin vertaamalla 
kasvua LGG-kannan kanssa. Toisin kuin LGG, joka ei kasvanut maidossa, LAB49 
kasvoi hyvin, ja saavutti stationäärivaiheen noin 12 tunnissa. LAB49-kantaa voidaan 
pitää ei-geneettisesti-muunneltuna elintarvikekelpoisena paranneltuna LGG-versiona, 
jota voitaisiin käyttää hapatteena maitotuotteissa.
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1 INTRODUCTION
1.1 Probiotics, the “good bugs”
1.1.1 Definition, classification, and source of probiotics
Microorganisms, such as archaea, bacteria, fungi, protozoans, and even virus, are not 
always in good reputation. People tend to think of pathogens, disease, corruption, or 
spoilage when microorganisms are mentioned. However, the truth is that 
microorganisms are not all “bad bugs”, instead there is a certain portion of “good bugs” 
that are beneficial to human and animals, for example probiotics. According to the 
definition of FAO/WHO, probiotics are “live microorganisms which when 
administered in adequate amounts confer a health benefit on the host” (Food and 
Agriculture Organization and World Health Organization Expert Consultation, 2001).
The concept “probiotics” originates in 1954 from the Greek word meaning “for life” 
(Binns, 2013). Nevertheless, for centuries people have realized the benefits of 
fermented food that contains live microbes. In academia, the idea that consuming 
fermented foods may connect to an improved and prolonged life is attributed to the 
work of the Nobel Prize winner, Elie Metchnikoff (Metchnikoff, 1907). Within a 
century, thousands of studies about microbes having beneficial effects on humans have 
been emerging, and the amount of commercial products related to “probiotics” has 
rocketed sky-high. Such increasing in both academia and industry has led to misuse of 
the term “probiotics” and misleading claims. In 2013, an expert panel by the 
International Scientific Association for Probiotics and Prebiotics (ISAPP) suggested 
that under two scenarios the term “probiotics” cannot be used: a) fermented foods with 
undefined microbial content; b) undefined consortia, including fecal microbiota 
transplant (Hill et al., 2014). Table 1 shows the acknowledged microorganisms that 
confer probiotic effects in human so far, bacteria like Lactobacillus spp., 
Bifidobacterium spp., and yeast (Saccharomyces boulardii) are included.
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Table 1. Microorganisms used as probiotic in human. Modified according to the schemes of Senok et 
al., 2005, Williams, 2010, and Zommiti et al., 2020.
Lactobacillaceae a Bifidobacterium spp. Other bacteria Yeast
Lactobacillus acidophilus B. adolescentis Bacillus clausii Saccharomyces boulardii
Lactobacillus amylovorus B. animalis Bacillus coagulans
Lactobacillus bulgaricus b B. bifidum Bacillus subtlis
Lacticaseibacillus casei B. breve Lactococcus lactis
Lactobacillus crispatus B. infantis Enterococcus faecalis
Limosilactobacillus fermentum B. lactis Enterococcus faecium c
Lactobacillus gasseri B. longum Escherichia coli Nissle 1917






a The genus name under Lactobacillaceae family are according to the taxonomic reclassification of Zheng 
et al., 2020, in which the genus Lactobacillus was reclassified into 25 genera under the Lactobacillaceae 
family; in this thesis, the new taxonomic names will be adopted, and the abbreviation “L.” still refers to 
“Lactobacillus” when the species of Lactobacillus are mentioned.
b The probiotic activity is still debated (Uriot et al., 2017). 
c Safety concerns remain because of potential pathogenicity and vancomycin resistance.
In daily life, for adults there are two main ways of obtaining probiotics, i.e., from foods 
supplemented with probiotics, or directly from dietary supplements. People may also 
directly use probiotic pills or capsules, in which high dose of targeted microbes are 
supplied. For infants, the mother milk is an important source of acquiring potential 
probiotics like Bifidobacterium, and this is also a crucial process for forming the normal 
gut microbiota of infants’ (Peirotén et al., 2018). Potential probiotics can be isolated 
from human microbiota (gut, skin, urogenital), fermented foods, and environment (soil, 
plants, animals) (Cunningham et al., 2021).
1.1.2 Properties and health benefits of probiotics
The presently acknowledged probiotics are well-selected and characterized strains, with 
scientific evidence of their capacity to confer health benefits on the host when 
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consumed in adequate amounts. The core feature of probiotics is that they should be 
safe to humans and not have pathogenic properties. Besides, probiotics aimed for the 
intestine must survive under the harsh condition, e.g., acid in stomach, bile and enzymes 
of small intestine, in order to lively exert their functions in gastrointestinal (GI) tract. 
From the perspective of production and ingestion, probiotics should be easily cultured 
to a large scale and maintain its viability in food product or supplement (Binns, 2013). 
In the recent decades, some probiotic strains have displayed promising effects in the 
topical application of skin (Blanchet-Réthoré et al., 2017; Lopes et al., 2017; 
Muizzuddin et al., 2012), nose (Michalickova et al., 2016; Van den Broek et al., 2018), 
and vagina (Coste et al., 2012; Gille et al., 2016). While this section will focus on the 
health benefits of “traditional probiotics” used by oral administration and exert their 
functions through human GI tract. The effects of many probiotic strains or their 
combinations have been extensively evaluated clinically. Clinical significance of 
probiotics is mainly indicated at their roles in metabolic disorders (e.g., obesity, 
diabetes), dysbiosis, gastrointestinal disorders (e.g., antibiotic-associated diarrhea, 
constipation), depression, anxiety, and mental disorders. Selected clinical studies 
evaluating the benefits of probiotics in human are shown in Table 2.
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Table 2. Selected clinical studies evaluating the benefits of probiotics in human. Modified according 
to the schemes of Zommiti et al., 2020.




Decreased body weight, increased fibrinogen levels Agerholm-Larsen et al., 
2000
Lactobacillus gasseri SBT2055 Decreased BMI and arterial blood pressure values Kadooka et al., 2013
Bifidobacterium, Streptococcus 
thermophilus
Improved lipid profile, insulin sensitivity, and decreased 
C-reactive protein
Rajkumar et al., 2014
Lactobacillus acidophilus La5, 
Bifidobacterium animalis BB12
Decreased fasting glucose concentration, increased 
homeostasis model assessment of insulin resistance
Ivey et al., 2015
Type-2 diabetes
Lactiplantibacillus plantarum A7 Decreased methylation process and superoxide 
dismutase
Hariri et al., 2015
Limosilactobacillus reuteri 
NCIMB 30242
Decreased low-density lipoprotein cholesterol by 11.64% 
and total cholesterol by 9.14% in hypercholesterolemic 
adults
Jones et al., 2012
Lactobacillus acidophilus A significant reduction was found in low-density 
lipoprotein




Escherichia coli Nissle 1917, 
Lacticaseibacillus casei Lcr35
Alleviated the symptoms of functional constipation in 
adults
Dimidi et al., 2014
Bifidobacterium lactis Improve the whole gut Bifidobacterium lactis




diarrhea, inflammatory bowel 
disease
Saccharomyces boulardii Decreased diarrhea rates in children receiving probiotic 
yeast (7.5%) compared to those receiving placebo (23%)
Kotowska et al., 2005
Escherichia coli Nissle 1917 Alleviated the symptoms of inflammatory bowel disease Behnsen et al., 2013
Bacillus clausii Alleviated the symptoms of acute diarrhea in children Ianiro et al., 2018
Saccharomyces boulardii A protective role in preventing antibiotic-associated 
diarrhea after intake of 5×109 CFU/day
Johnston et al., 2011
Lacticaseibacillus rhamnosus GG Decreased the duration of acute gastroenteritis in 
children
Szajewska et al., 2013
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Cancer and side effects 
associated with cancer
Lactobacillus acidophilus and 
Bifidobacterium spp.
Inhibited the growth of tumor cells, produced anti-
carcinogens and reduces cancer risks
Vasiljevic and Shah, 2008
Lacticaseibacillus rhamnosus 573 Patients experienced less abdominal discomfort, less 
hospital care and lower chemo dose were needed
Österlund et al., 2007
Depression, anxiety, and mental 
disorders
Lactobacillus helveticus R0052 
Bifidobacterium longum R0175
Decreased aggressive and ruminative thoughts in 
response to sad mood
Messaoudi et al., 2011
Bifidobacterium bifidum W23, 
Bifidobacterium lactis W52, 
Lactobacillus acidophilus W37, 
Levilactobacillus brevis W63, 
Lacticaseibacillus casei W56, 
Ligilactobacillus salivarius W24, 
and Lactococcus lactis (W19 and 
W58)
Significantly reduced overall cognitive reactivity to sad 
mood
Steenbergen et al., 2015
1.1.3 Overview of the probiotic yeast Saccharomyces boulardii
Saccharomyces boulardii is the only yeast used as probiotics, and the type strain is S. 
boulardii CNCM I-745 (or S. boulardii Hansen CBS 5926). In 1923, a French scientist 
Henri Boulard isolated S. boulardii from tropical fruit lychee in Southeast Asia. Later 
in 1962, the lyophilized powder of S. boulardii was commercially available from 
Laboratoires Biocodex (Montrouge, France) and mainly used for antibiotic-associated 
diarrhea (McFarland and Bernasconi, 1993). Nowadays, S. boulardii is regulated as 
dietary supplement for human (Venugopalan et al., 2010) and can be easily found in 
pharmacy as capsules or pills.
S. boulardii was first identified as a distinct species in the genus Saccharomyces since 
it does not sporulate and metabolize galactose (McFarland, 1996; Mitterdorfer et al., 
2001). However, molecular typing (Edwards-Ingram et al., 2004; Fietto et al., 2004; 
Mitterdorfer et al., 2002) and the comparative genomic analysis (Khatri et al., 2017) 
argued that S. boulardii should be considered as a strain of Saccharomyces cerevisiae 
instead of a different species. Mitterdorfer et al., 2002 found that S. boulardii clustered 
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to a separate group, but belonged to S. cerevisiae species. Khatri et al., 2017 compared 
the genomes of 5 S. boulardii strains with 145 S. cerevisiae strains. The genetic 
characteristic of S. boulardii was that it did not carry Ty elements Ty1, Ty3, Ty4 and 
associated long terminal repeat, while complete Ty2 and Ty5 were identified. More 
importantly, S. boulardii and S. cerevisiae shared more than 99% relatedness in genome, 
and strains of S. boulardii were closely related to the wine strains of S. cerevisiae.
Even though they are genetically similar, S. boulardii does own some unique 
physiological phenotypes that make it a probiotic yeast. Comparing with S. cerevisiae, 
the heat and acid resistance of S. boulardii is superior, and its optimal growth 
temperature is 37 °C (Fietto et al., 2004). S. boulardii also resists the proteolytic 
cleavage (Fietto et al., 2004). These features guarantee that S. boulardii could tolerate 
the harsh condition of human stomach and GI tract, thus reaching the target organ to 
exert its function. Since S. boulardii is not a natural colonizer in the human intestine, it 
can easily be cleared within 3-5 days (Klein et al., 1993). In a word, S. boulardii has a 
long history of applying as probiotics and it is similar to the well-known S. cerevisiae, 
but with unique properties.
In addition to the physiological phenotypes of S. boulardii that enable its better survival 
in GI tract, the safety and function also matter for probiotics. S. boulardii is granted as 
GRAS (generally regarded as safe) status by the Food and Drug Administration (FDA) 
of USA (Czerucka et al., 2007), and QPS (qualified presumption of safety) by European 
Food Safety Authority (EFSA) (EFSA Panel on Biological Hazards (BIOHAZ) et al., 
2018). Although S. boulardii has been linked to fungemia in immunocompromised 
individuals (Santino et al., 2014), no fungemia cases caused by S. boulardii were 
reported in clinical trials (Kelesidis and Pothoulakis, 2012; McFarland, 2017). The 
benefits of S. boulardii in gastrointestinal diseases have been widely assessed in clinical 
trials. It has been summarized by McFarland, 2017 that 90 randomized controlled trials 
have been done within 40 years. These trials investigated the efficacy of S. boulardii in 
15 types of disease, including diarrheas like antibiotic-associated diarrhea (D'souza et 
al., 2002; Surawicz et al., 1989; Szajewska and Mrukowicz, 2005), traveler’s diarrhea 
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(Kollaritsch et al., 1993; McFarland, 2007), AIDS-associated diarrhea (Saint-Marc et 
al., 1995; Villar-García et al., 2015), acute diarrhea in children (Dinleyici et al., 2015; 
Feizizadeh et al., 2014); IBD (inflammatory bowel disease) like Crohn’s disease
(Guslandi et al., 2000), ulcerative colitis (Guslandi et al., 2003); IBS (irritable bowel 
syndrome) (Maupas et al., 1983); Helicobacter pylori infections (Cremonini et al., 2002; 
Duman et al., 2005) and so on.
The mechanisms of action of S. boulardii to display its probiotic benefits have been 
described as multiple ways. They mainly take place through pathogen binding, antitoxin 
effects, trophic actions on the intestinal mucosa, and immune regulations (Figure 1).
Figure 1. Mechanisms of action of S. boulardii to display its probiotic benefits. Modified from the 
figure of Pais et al., 2020 and the scheme of Kelesidis et al., 2012. Briefly, S. boulardii displays its 
benefits through: a) directly binding and excluding intestinal pathogens (Chen et al., 2006; Czerucka et 
al., 1994; Dalmasso et al., 2006; Geyik et al., 2006; Herek et al., 2004), the yeast cell wall components 
are responsible for the binding; b) deactivating the toxin produced by pathogens, mainly S. boulardii 
produces serine protease (Pothoulakis et al., 1993), phosphatase (Buts et al., 2006; Castagliuolo et al., 
1996), or some unknown proteins (Czerucka et al., 1994) for toxin lysis; c) stimulating the trophic effects 
on intestinal epithelial cells, for example stimulating producing brush border membrane (BBM) enzymes 
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(Buts et al., 1986), polyamines (Buts et al., 2002; Jahn et al., 1996; Schneider et al., 2005) and restoring 
the normal level of colonic short chain fatty acids (SCFAs) (Breves et al., 2000; Sezer et al., 2009) to 
enhance the intestinal barrier; d) acting as an immune stimulant (Rodrigues et al., 2000) or reducing pro-
inflammatory cytokines (Generoso et al., 2011).
1.1.4 Overview of the probiotic bacterium Lacticaseibacillus rhamnosus GG
As summarized in Table 1, majority of the probiotics, with the exception of the 
probiotic yeast S. boulardii, belong to the bacterial domain. Specifically, the genus 
Lactobacillus is the dominant group among the probiotics market and recently 
reclassified into several genera (Zheng et al., 2020). At present, many strains from L. 
acidophilus, Lactiplantibacillus plantarum, Lacticaseibacillus casei, L. johnsonii and 
Lactiplantibacillus rhamnosus are commercially available with certain trademarked 
names. For example, Lacticaseibacillus rhamnosus GG (ATCC 53103, LGG) is known 
under several commercial names, e.g., ActifitPlus®, Gefilus®, LGG®, Onaka He GG! ®, 
and Vifit® (Saxelin et al., 2005). The wide utilization of LGG in industry is a result of 
extensive studies that have demonstrated the safety and benefits of this famous strain. 
Unlike S. boulardii, LGG was isolated from healthy human intestine by Sherwood 
Gorbach and Barry Goldin in 1983. The patented name of LGG in 1989 (Gorbach and 
Goldin, 1989) was L. acidophilus GG, and it was later reclassified into a strain of L. 
rhamnosus. Notably, Zheng et al., 2020 proposed a new classification of genus 
Lactobacillus into 25 genera according to the whole genome sequences analysis, in 
which LGG should be called Lacticaseibacillus rhamnosus GG.
After its discovery, LGG has become one of the most broadly researched probiotic 
strains and thus the safety and benefits of LGG have been well documented. Studies 
have shown the safe usage of LGG covering varied-age or -status people: newborns 
(Arvola et al., 1999), preterm infants (Underwood et al., 2009), children (American 
Academy of Pediatrics, 2001; Hojsak et al., 2010; Vanderhoof et al., 1999), adults 
(Szajewska and Kołodziej, 2015) and in the elderly (Hatakka et al., 2007); pregnant 
women (Lahtinen et al., 2009), and HIV patients (Salminen et al., 2004). Generally, 
LGG is safe for human consumption and its QPS (EFSA Panel on Biological Hazards 
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et al., 2018) and GRAS (Food and Drug Administration, 2019) status have been 
acknowledged. Clinical trials have shown the efficacy of LGG, mainly in alleviating 
GI disorders like acute rotavirus gastroenteritis (Fang et al., 2009; Oberhelman et al., 
1999; Szajewska et al., 2001), antibiotic-associated diarrhea (Arvola et al., 1999; 
Thomas et al., 2001; Vanderhoof et al., 1999), IBS (O'Sullivan and O'Morain, 2000; 
Pedersen et al., 2014), travelers’ diarrhea (Hilton et al., 1997; Oksanen et al., 1990), 
abdominal pain-related functional gastrointestinal disorders in children (Bausserman 
and Michail, 2005; Francavilla et al., 2010; Gawrońska et al., 2007), acute diarrhea in 
children (Guandalini et al., 2000; Misra et al., 2009; Ritchie et al., 2010); enhancing 
microbiota balance (Apostolou et al., 2001; Gueimonde et al., 2006; Lahti et al., 2013); 
modulating immune response (Kekkonen et al., 2008; Schultz et al., 2003); preventing 
onset of allergic diseases (Isolauri et al., 1991; Kalliomäki et al., 2001; Majamaa and 
Isolauri, 1997).
Apart from the ability of surviving and proliferating in gastric acid and bile, a 
noteworthy feature of LGG is its strong adhesion ability to epithelial cells of intestine. 
As claimed in the patent of Sherwood Gorbach and Barry Goldin in 1989, LGG is 
characterized “in that an average of at least 50, more preferably at least 100, of the 
bacteria can adhere to one human small intestinal mucosal cell after five minutes 
incubation of the bacteria with the cells”. The in vivo human intervention study of 
Kankainen et al., 2009 also revealed that LGG could stay longer and in higher density 
in human intestinal tract compared to L. rhamnosus LC705. This feature enables active 
interactions between LGG and intestinal epithelial cells or immune cells, and the so-
called LGG-host interactions (Bron et al., 2012; Segers and Lebeer, 2014) are also 
important mechanism of action responsible for LGG’s probiotic benefits. From the 
molecular insights, Segers and Lebeer, 2014 proposed several ways engaging in LGG-
host interactions, i.e., pili-mediated adhesive capacity, lipoteichoic acid as key immune 
effector, major secreted proteins as probiotic effectors, exopolysaccharides as 
modulating adaptation factors, and secreted antimicrobials.
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1.2 Modification and development on the property of probiotics
1.2.1 Genetic engineering as a way to develop next-generation probiotics
Considering the increasing commercial and clinical relevance of probiotics, the 
modification and development of the properties of probiotics as a new frontier in 
probiotics research have attracted many scholars’ interests. Modifying the properties of 
probiotics is mainly targeted to: a) enhancing the resistance of probiotics to the stresses 
encountered during preparation and storage of the delivery matrices; b) enhancing in 
vivo resistance of probiotics to the stresses in human GI tract; and c) enhancing the 
benefits of probiotics by engineering them for secretion of bioactive molecules, or 
targeting specific pathogens/toxins (Sleator and Hill, 2008). The third-type modified 
probiotics could be regarded a kind of next-generation probiotics (NGPs).
The term NGPs is a new concept proposed to describe live microorganisms that are not 
traditionally used as probiotics, but own potential health benefits to humans, even 
though many of these are still at an early stage of investigation (Langella et al., 2019; 
Martín and Langella, 2019; O'Toole et al., 2017). On the other hand, as summarized by 
O'Toole et al., 2017, NGPs are “more likely to be delivered under a drug regulatory 
framework” like live biotherapeutic product (LBP). The formally recognized concept 
by FDA (Food and Drug Administration, 2016) and European Directorate for the 
Quality of Medicines and healthcare (EDQM) (European Pharmacopoeia Commission, 
2019), LBP, is defined by FDA as a biological product that “contains live organisms; is 
applicable to the prevention, treatment, or cure of a disease or condition of human 
beings; is not a vaccine”. Even though NGPs conform to the definition of LBP, it is 
suggested that the term LBP should not be systematically applied to replace NGPs. For 
one thing, the term NGPs indicates that they are different from traditional probiotics; 
for another thing, NGPs include microorganisms that are being investigated and do not 
correspond to a defined product yet, e.g., genetically modified microorganisms and 
potential beneficial commensal bacteria (Martín and Langella, 2019; O'Toole et al., 
2017).
18
Two strategies are being employed to develop NGPs (O'Toole et al., 2017). Like current 
probiotics, the first strategy is to evaluate if a specific strain carries health phenotype 
when administered in sufficient quantities. For example, the benefits of Bacteroides 
xylanisolvens DSM 23694 (Ulsemer et al., 2016), Bacteroides ovatus D-6 (Ulsemer et 
al., 2013), Clostridium butyricum MIYAIRI 588 (Shimbo et al., 2005; Woo et al., 2011), 
and Faecalibacterium prausnitzii (Rossi et al., 2016; Song et al., 2016) have been 
evaluated. Another strategy is to apply well-characterized probiotic strains, GRAS 
microorganisms, or commensals as delivery vehicles for bioactive molecules like anti-
inflammatory cytokines, transforming growth factor, or bacteriocins. The advantages 
of modifying and using aforementioned microbes as delivery vehicles are that they are 
usually identified as not producing virulence factors, and will be tolerated by the host, 
and if chosen carefully, may not even colonize the host.
In the second strategy, targeted modification of the properties of the microorganisms is 
needed, in such case, genetic engineering could serve as a useful tool. Taken the genetic 
engineering of probiotics as examples, the serine protease inhibitor Elafin was 
expressed in L. lactis, and the administration of the modified strain reduced 
inflammation in a mice model of colitis (Motta et al., 2012). In addition, interleukin 10 
(IL-10) controlling allergen sensitivity (Frossard et al., 2007) and trefoil factor 1 
controlling oral mucositis (Robert and Steidler, 2014), were produced by different L. 
lactis strains and proved to be useful in preclinical trials in mice. A plasmid expressing 
anti-HIV hybrid peptides was introduced into probiotic strain E. coli Nissle 1917, and 
mice trial showed that the modified probiotic inhibited HIV infection by blocking its 
entry into host cells (Rao et al., 2005). Plasmid-based techniques have also been applied 
in the genetic engineering of Lactiplantibacillus plantarum (Shi et al., 2014) and 
Lacticaseibacillus casei (Alvarez-Sieiro et al., 2014; Liu et al., 2014; Qiu et al., 2013). 
Besides, several bioactive molecules were engineered to be secreted in S. thermophilus 
(Selle et al., 2015), Limosilactobacillus reuteri (Oh and van Pijkeren, 2014; Van 
Pijkeren and Britton, 2014) using CRISPR-Cas9, in L. lactis and Limosilactobacillus 
reuteri (van Pijkeren and Britton, 2012; van Pijkeren et al., 2012), and 
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Lactiplantibacillus plantarum (van Pijkeren and Britton, 2012) using chromosome 
modification system.
1.2.2 Studies on the modification and development of S. boulardii and LGG
To secrete bioactive molecules, various laboratory strains of S. cerevisiae have been 
genetically engineered. While natural auxotrophic mutants of S. boulardii have not been 
reported, only URA3 mutant has been generated by UV mutagenesis (Hamedi et al., 
2013; Hudson et al., 2014) and CRISPR-cas9 (Bagherpour et al., 2018; Liu et al., 2016). 
Douradinha et al., 2014 investigated factors concerning the genetic manipulation of S. 
boulardii, such as plasmid transformation and screening of positive strains. In the 
newest study of Jin et al., 2021, four signal peptides, namely chicken lysozyme signal 
peptide (CL), α-mating factor signal peptide (α-MF) from S. cerevisiae, Sta1 signal 
peptide (STA1) from Saccharomyces diastaticus, and Sed1 signal peptide (SED1) from 
S. cerevisiae were tested for controlling the production of target substance. SED1 was 
shown to be the most efficient signal peptide in producing the endo‑type β‑agarase 
BpGH16A in S. boulardii ATCC MYA-796.
Several studies have been performed aiming to modify or develop the properties of S. 
boulardii by genetic engineering. Glucoamylase (Latorre-García et al., 2008), mouse 
IL-10 (Michael et al., 2013; Pöhlmann et al., 2013), and Eimeria tenella microneme-2 
antigen (Wang et al., 2014) were produced in wild-type S. boulardii using antibiotics 
selection. Using URA3 auxotrophic mutant of S. boulardii as host, green fluorescent 
protein (GFP) (Hudson et al., 2014), human lysozyme (Liu et al., 2016), ovalbumin 
(OVA) (Bagherpour et al., 2018), and endo-type β-agarase (Jin et al., 2021) were 
produced. Three studies have evaluated the effects of engineered S. boulardii with mice 
model. Michael et al., 2013 tested the anti-inflammatory function of IL-10 producing 
S. boulardii in the colitis mice model. No significant differences were observed between 
the treated and untreated groups, suggesting that IL-10 was not sufficiently secreted 
into the intestine to decrease the inflammatory response. Hudson et al., 2014 revealed 
in their studies that the GFP-producing S. boulardii strain could be recovered from the 
Peyer’s patches of mice fed with this strain, and the isolated yeasts still carried the GFP 
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production capacity. Via mice oral administration, Bagherpour et al., 2018 used the 
OVA-producing S. boulardii to deliver antigenic peptide ovalbumin into intestinal 
lumen and observed an increased antibody response in treated group compared with 
control group. It has been suggested that probiotic S. boulardii should be desirable 
vehicle for expressing and delivering functional molecules, as it carries native benefits 
and tolerance to human GI tract, and most importantly it will not exchange genetic 
material with other microorganisms (Palma et al., 2015; Pöhlmann et al., 2013).
As for LGG, very few studies aiming to modify or improve its properties have been 
implemented. Vélez et al., 2007 deleted dltD gene encoding DltD membrane protein in 
LGG, which resulted in modifications of the bacterial cell surface properties; later, the 
dltD LGG mutant was applied in a mice colitis model, and the mutant displayed an 
improved therapeutic efficacy compared to wild-type LGG (Claes et al., 2010). The 
HIV-inhibiting lectin, griffiths, was produced in LGG and the recombinant strain 
showed in vitro anti-HIV activity against M-tropic and T-tropic HIV-1 strains (Petrova 
et al., 2018). In addition, novel fluorescent derivative (Spacova et al., 2018) and highly 
mucus-adherent derivative (Rasinkangas et al., 2020) of LGG were generated, which 
could be used to further study the LGG-host interactions. On the other hand, one patent 
(Heidtman et al., 2015) described the generation of a LGG strain that its lactose 
utilization deficiency has been fixed, the details are elaborated in section 1.4.2.
1.3 LAB bacteriocins and Leuconostoc bacteriocin leucocin C 
1.3.1 LAB bacteriocins
Antimicrobial peptides (AMPs) are molecules that exist in several organisms like 
bacteria, plants, animals and human, and they play an important role in the defense 
system against pathogens. In bacteria, the gene-encoded AMPs are called bacteriocins, 
and they primarily kill closely related organisms of the producer. It has been proposed 
that bacteriocins may be viable alternatives to antibiotics due to the advantages of 
bacteriocins: in vitro and in vivo efficacy, the availability of both broad- and narrow-
spectrum peptides and the possibility of in situ production by probiotics (Cotter et al., 
21
2013). Most importantly, unlike antibiotics that are secondary metabolites, the 
biosynthetic mechanisms of bacteriocins are comparatively simple (Perez et al., 2014), 
making bacteriocins easily bioengineered (Cotter et al., 2013; Perez et al., 2014). 
Bacteriocins produced by LAB have received much attention because of their 
antimicrobial activity against foodborne pathogens like Listeria monocytogenes and 
Staphylococcus aureus (Arqués et al., 2011), Bacillus cereus (Kaya and Simsek, 2019), 
Clostridium perfringens (Voidarou et al., 2020); or food spoilage microbes like 
Pseudomonas fluorescens (Voidarou et al., 2020) and Pediococcus damnosus (Ahn et 
al., 2017). Studies have shown that a number of LAB including Lactobacillus, 
Lactococcus, and Leuconostoc secrete bacteriocins, of which many have been well 
characterized (Zacharof and Lovitt, 2012). The most well-known LAB bacteriocin is 
nisin, which has been accepted as a safe food additive and commercially used to 
facilitate the food preservation (Gálvez et al., 2007). 
Presently, 230 characterized bacteriocins have been archived by the online database 
Bactibase (http://bactibase.hammamilab.org/main.php). The LAB (order 
Lactobacillales) are the predominant group of producers. In 2019, Kassaa et al., 2019 
developed a dedicated database for LAB bacteriocins: LABiocin (www.labiocin.net), 
collecting 517 LAB bacteriocins from research articles up to August 2017. Notably, 
Lactobacillus (old classification) made up 30.95% of the producer genus, followed by 
Enterococcus (24.18%) and Streptococcus (16.83%). The antimicrobial spectrum 
showed that 62.08% of the archived LAB bacteriocins could inhibit Gram-positive 
bacteria, and 22.05% could inhibit both Gram-positive and Gram-negative bacteria.
Put aside the bacteriocins containing non-protein moieties, LAB bacteriocins are 
generally classified into three categories (Class I, II, and III). The proposed 
classification and typical bacteriocin are presented in Figure 2. Class I and II 
bacteriocins are small peptides (<10 kDa) and are heat stable, while class III 
bacteriocins are generally considered to be large ( 10 kDa) and thermo-labile AMPs. 
Specifically, class I bacteriocins need post-translational modifications before they are 
biologically active. For class II bacteriocins modifications are not needed, and they 
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usually have a narrow spectrum. Class III are unmodified AMPs that consist of 
















































Figure 2. Proposed scheme of classification for LAB bacteriocins. Modified according to the schemes 
of Alvarez-Sieiro et al., 2016 and Wan, 2017.
1.3.2 Leuconostoc bacteriocin leucocin C
Leucocin C is a class IIa (also known as pediocin-like) bacteriocin secreted by 
Leuconostoc species, mainly Ln. carnosum and Ln. mesenteroides. Besides leucocin C, 
the bacteriocins produced by Leuconostoc species known as leucocins are leucocin A, 
leucocin B, and other leucocins like leucocin Q, N and so on. There are also some other 
23
Leuconostoc bacteriocins named as mesentericins, which are produced by Ln. 
mesenteroides strains. So far, more than 40 Leuconostoc bacteriocins have been 
characterized (Wan, 2017).
Like other class IIa bacteriocins, leucocin C is best known for its antimicrobial activity 
against the foodborne pathogen L. monocytogenes. It has been well accepted that the 
class IIa bacteriocins exert their function through a fast-acting system: holing the cell 
membrane of target microbes and causing internals release (Eijsink et al., 2002; Tiwari 
et al., 2015). In detail, three steps are included in the model of action for class IIa 
bacteriocins killing: first, the bacteriocin attaches to the extracellular loop of Man-PTS 
(mannose phosphotransferase system) IIC domain; then, the C-terminal helix of the 
bacteriocin breaks into the cytoplasmic membrane after interacting with 
transmembrane helices of the IIC domain, and finally forms pores and leading to cell 
death (Diep et al., 2007; Kjos et al., 2011).
So far, the amino acid sequence of leucocin C from six different producers have been 
published (Budde et al., 2003; Fimland et al., 2002; Papathanasopoulos et al., 1998; 
Vaughan et al., 2001; Wan et al., 2013), among which only Wan et al., 2013 performed 
the genetic characterization of leucocin C from Ln. carnosum 4010. The new culture, 
Ln. carnosum 4010, was isolated by Budde et al., 2003 from vacuum-packed meat 
products; they found that the strain 4010 displayed strong anti-listerial activity. By N-
terminal sequencing, Budde et al., 2003 identified the purified and characterized 
leucocin B-4010, which is actually closely similar to leucocin C TA33a 
(Papathanasopoulos et al., 1998). In 2013, the work from our group characterized the 
genes encoding leucocins A and C in Ln. carnosum 4010, and leucocin C cluster 
included two intact operons in the plasmid; the gene encoding the mature peptide of 
leucocin C was cloned and expressed in L. lactis, and heterologously secreted leucocin 
C was active in killing L. monocytogenes (Wan et al., 2013). With the availability of the 
genetic information, more molecular-biological work could be done to either increase 
the activity or expand the specificity of leucocin C against target microbes. For example, 
Liu et al., 2013 constructed a leucocin C-producing E. coli that was equipped with cell 
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wall binding domain of Listeria phage endolysin. In this way the E. coli bound to 
Listeria cells and exhibited enhanced ability to kill L. monocytogenes.
1.3.3 Application of LAB bacteriocins in foods
As mentioned in 1.3.1, LAB bacteriocins are mainly applied in foods as bio-
preservatives against foodborne pathogens or food spoilage microbes. For such 
application, there are three considerations: first, the LAB bacteriocins are produced by 
lactic acid bacteria that are generally considered to be food-grade; second, unlike 
antibiotics, bacteriocins do not show toxicity towards eukaryotic cells (Perez et al., 
2014); third, most LAB bacteriocins are heat-stable and maintain their activity over a 
wide range of pH. Thus, considering that the external additives used in food have to be 
safe to humans and tolerate the “natural intrinsic hurdles” of foods, and the technologies 
used in food processing, the features of LAB bacteriocins make them good candidates 
for use in foods to improve the safety (And and Hoover, 2003; O'Sullivan et al., 2002), 
quality (O'Sullivan et al., 2002), or even flavor (Garde et al., 2002; O'Sullivan et al., 
2003). The utilization of bacteriocins in food preservation may also reduce the needs 
for chemical or physical treatments, resulting in more naturally preserved foods.
Presently, only nisin and pediocin PA1/AcH, for example commercial products Nisaplin 
(DuPont Nutrition & Biosciences) and ALTA 2431 (Quest International), respectively, 
are widely used in food industry. There are three main ways of introducing LAB 
bacteriocins into foods: a) in situ secretion by the producer strain added in fermented 
food or beverage, thereby the purification of bacteriocins is not needed; b) if the dose 
of bacteriocins has to be controlled, then purified or semi-purified bacteriocins like 
Nisaplin can be added into food either directly, or by the incorporation to food 
packaging films (Franklin et al., 2004; Mauriello et al., 2005); c) using food ingredients 
like ALTA 2431 containing natural metabolites including organic acids and pediocin of 
LAB is also a method of introducing LAB bacteriocins into food. In addition, studies 
have shown that use of LAB bacteriocins could also be combined with traditional food 
processing techniques such as heating (Boziaris et al., 1998; Budu-Amoako et al., 1999), 
adding of chelating agents (Cutter and Siragusa, 1995) or chemical antimicrobials 
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(Mansour and Millière, 2001; Periago and Moezelaar, 2001), high hydrostatic pressure 
(Masschalck et al., 2001), and pulsed electric field (Pol et al., 2000).
Studies in recent years have clearly demonstrated the benefits of using LAB 
bacteriocins in food. For example, Arqués et al., 2011 found a strong synergistic effect 
against L. monocytogenes when nisin, lacticin 481 or enterocin AS-48 was used 
together with reuterin in milk. Besides, enterocin AS-48 could increase the thermal 
sensitivity of Bacillus licheniformis (Grande et al., 2006), a bacterium that forms slime 
and causes ropy appearance in cider (Larpin et al., 2002), and thus makes it more 
efficiently deactivated when combined with heat treatment. Nisin applied on fresh-cut 
fruits could reduce up to 3.2 log of L. monocytogenes spiked on honeydew melon slices, 
and up to 2.0 log on apple slices (Leverentz et al., 2003). In particular, using LAB 
bacteriocins to inhibit the highly pathogenic and foodborne L. monocytogenes has 
drawn a lot of attention of scientists, since L. monocytogenes is ubiquitously found in 
meat (Kurpas et al., 2018; Pesavento et al., 2010), raw vegetables (Beuchat, 1996; 
Farber et al., 1998), and dairy products (Hayes et al., 1986; Rudol and Scherer, 2001) 
and it can cause human listeriosis. Studies regarding using nisin (Leverentz et al., 2003), 
leucocin C (Fu et al., 2018), and bacteriocin PA-1 (Pucci et al., 1988) in L. 
monocytogenes-contaminated foods have indicated the effectiveness of bacteriocins. As 
for leucocin C, Budde et al., 2003 added the leucocin C-producing strain Ln. carnosum 
4010 to vacuum-packaged meat sausage, and the viable cells of L. monocytogenes 
decreased below 10 CFU/g after 21-days storage at 5 ºC. Fu et al., 2018 co-expressed 
nisin Z and leucocin C in L. lactis N8. After that, they confirmed that the supernatant 
containing leucocin C and nisin Z reduced the viable cell count of L. monocytogenes 
inoculated into pasteurized milk by 2 log after 16 h at 4 ºC.
Traditionally, bacteriocins that are added into foods are mainly for the purpose of 
preservation or safety of foods. As bacteriocins could be introduced into foods through 
adding bacteriocin-producing probiotics, in such case foods in turn could act as vehicles 
for delivering bacteriocins into GI tract to inhibit pathogenic bacteria (Cotter et al., 
2005; Cotter et al., 2013). Bacteriocins directly applied in food may be inactivated by 
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the interaction with food components like fat (Degnan et al., 1993) or protein, or by the 
proteolytic enzymes of the stomach. Bacteriocins-producing probiotics added in foods 
could reach the GI tract alive, allowing the in vivo production of bacteriocins.
1.4 Lactose and casein utilization deficiency of LGG
1.4.1 Lactose intolerance and cow’s milk protein allergy (CMPA)
Milk is an important source of minerals, vitamins, carbohydrates, and proteins for 
humans, yet some disorders like lactose intolerance and cow’s milk protein allergy 
(CMPA) caused by milk ingestion in certain people cannot be ignored. There is 
approximately 4.8% lactose in bovine milk, and up to 7% lactose in human milk 
(Jenness, 1979; Ohlsson et al., 2017). Lactose intolerance is caused by the lack of 
endogenous lactase in the human small intestine. The decrease in the amount of lactase 
usually happens after weaning and can extend into adulthood. The prevalence of lactose 
intolerance is estimated to be 68% globally, and 28% in Western, Southern, and 
Northern Europe (Storhaug et al., 2017). Moreover, around 3% of infants are affected 
by CMPA (Gupta et al., 2011; Sicherer and Sampson, 2014), a type of immune system 
malfunction that is mainly triggered by casein and whey β-lactoglobulin in milk.
So far, the commonly used preventive measure for lactose intolerance and CMPA is 
consuming milk alternatives with reduced lactose and casein content (EFSA Panel on 
Dietetic Products, 2010), for example, hydrolyzed formulas and soy-based formulas. 
The use of probiotic or lactose- and/or casein hydrolyzing bacteria in dairy products is 
another candidate for alleviating the symptoms. In lactose intolerance, probiotics 
improve the lactose absorption through enhancing the overall hydrolytic capacity in the 
small intestine and increasing the colonic fermentation (Dhama et al., 2016). In addition, 
bacteria in fermented dairy products can decrease the lactose contents and bring active 
lactase into the intestine (He et al., 2008). Several probiotics have been reported to play 
a role in lactose intolerance prevention, such as B. animalis (Roškar et al., 2017), B. 
longum (He et al., 2008; Jiang et al., 1996), L. bulgaricus (Parra and Martínez, 2007; 
Rizkalla et al., 2000), and Lacticaseibacillus rhamnosus (Agustina et al., 2007) (strain 
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LMG P-22799). In terms of CMPA, the main probiotic used was LGG, which was 
usually supplied in extensively hydrolyzed formula, either hydrolyzed casein (Berni 
Canani et al., 2017; Berni Canani et al., 2012; Scalabrin et al., 2017) or hydrolyzed 
whey (Kirjavainen et al., 2003), to ease the symptoms and accelerate the acquisition of 
CMPA tolerance. When used in hydrolyzed formula for CMPA, the main benefits of 
LGG are mediating the gut immune response and boosting the intestinal mucosal barrier 
(Scalabrin et al., 2017). 
1.4.2 Lactose/casein utilization deficiency of LGG and ways to improve LGG
As aforementioned in 1.4.1, LGG could be added as a probiotic supplement in 
hydrolyzed formulas. Besides, LGG has also been added to several dairy products, such 
as yogurt, cheese, and fermented milk. However, studies have indicated that some dairy 
products like yogurt, cannot maintain an adequate level of viable probiotics during their 
shelf-life. Thus, their health value might be compromised in this respect (Heenan et al., 
2004; Schillinger, 1999; Shah et al., 2000; Shin et al., 2000). LGG does not metabolize 
lactose and casein, which limits cell growth and number in dairy products (Liptáková 
et al., 2008). It is known that LGG carries the lacTEGF gene cluster encoding the 
lactose-PTS operon (Kankainen et al., 2009), while the two mutations occurred in lacG 
(a phospho-β-galactosidase gene) and lacT (an anti-terminator gene) cause the lactose 
metabolization deficiency of LGG. The reason of casein metabolization deficiency of 
LGG has not been clarified. Using comparative genomic analysis, Kankainen et al., 
2009 did not find evident differences in the predicted enzymatic system for casein 
digestion between LGG and Lacticaseibacillus rhamnosus LC705, while the strain 
LC705 is capable of using casein. LGG does not carry the gene LC705_02680 encoding 
a subtilisin-like serine protease. However, this gene presents in the strain LC705, where 
it is predicted to be involved in casein degradation of LC705. Both strains carry intact 
genes encoding the cell envelope serine protease (PrtP) and maturation protein (PrtM), 
which are supposed to be responsible for casein degradation, for example in L. lactis 
(Wegmann et al., 2012). Nevertheless, it is not clear if PrtP or PrtM is expressed in 
LGG. 
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Efforts have been made to fix such deficiency of LGG. At genetic level, Heidtman et 
al., 2015 patented a LGG strain, which is capable of growing on lactose. This strain was 
generated by spontaneous mutagenesis using a lacT expression plasmid. Focusing on 
improving the growth of LGG in milk is another way. To realize such purpose, it is 
suggested that the milk matrices should be supplied carbohydrates that LGG could use 
such as glucose, or proteolytic enzymes, or partially hydrolyzed nitrogen sources such 
as yeast extract. Besides, Kort et al., 2015 used S. thermophilus C106 as adjuvant 
culture with LGG in fermenting milk in Africa, and LGG could reach a final density of 
1×109 CFU/ml. Genome‑scale metabolic model of LGG and S. thermophilus C106 
revealed that the folic acid, succinate, glycerol, and galactose released by S. 
thermophilus C106 during fermentation might be the reason of improved growth of 
LGG. Therefore, it is also feasible to select suitable starter strains to facilitate the 
growth of LGG in milk due to the starter’s native proteolytic activity, lactose 
degradation ability and other synergistic effects.
As summarized in 1.2, the properties of probiotics can be modified and improved by 
genetic engineering. If the ability deficiency in lactose/casein metabolization could be 
fixed by genetic engineering, LGG could be applied in milk fermentation to exhibit its 
dual effects in probiotic benefits with enhanced proliferation, and in reducing the 
chance of lactose intolerance/CMPA. In addition to the method of Heidtman et al., 2015, 
non-GMO transformation methods are also ideal techniques, for example, transduction 
and conjugation of natural phages, plasmids, or transposons (Börner et al., 2019). 
Conjugation naturally exists in bacteria, and the most common conjugation is the 
antibiotic-resistance transferring. Unlike the vertical transferring of DNA from parent 
to offspring, bacterial conjugation is a type of horizontal gene transfer (Keeling and 
Palmer, 2008) between cells, even though they are not genetically related. Regarding 
the topic of lactose/casein metabolization deficiency, conjugation has been used to 
transfer a pLP712 plasmid from a dairy strain L. lactis NCDO 712 into lactose-deficient 
strains (Gasson, 1990). The pLP712 plasmid contains the gene that encodes the protease 
for casein degradation as well as the genes for lactose catabolism. Thus, the dairy strain 
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L. lactis NCDO 712 carrying pLP712 could be considered as a donor for LGG to solve 
its lactose/casein metabolization issue by conjugation.
1.5 Use of LGG and S. boulardii in food
The idea of introducing probiotics into food as a strategy to facilitate food processing 
or preservation has been well accepted in the food industry. The purpose is to develop 
products containing live probiotics or their metabolites to realize the concept of “health-
promoting properties”; or utilize the antimicrobial characteristic of certain probiotics 
like bacteriocins-secreting LAB to improve the food safety and shelf life.
LGG has been widely used in food and many products have been developed, for 
example, in Finland there is a “Gefilus®” product series (Valio Oy, Helsinki, Finland), 
including juice, yogurt, buttermilk and kefir, in which LGG has been supplied. In 
academia, the effects of LGG in food processing and food preservation have been 
evaluated (Table 3).
Table 3. The effects of LGG used in food.
Purpose/product Description References
Food processing
Mixed jussara and mango juice LGG added presented a better survival rate under 
optimized condition obtained from this study
Prates et al., 2020
Hawthorn berry tea A functional food containing LGG with enhanced storage 
stability was developed
Lai et al., 2020
Fermented juice with blueberry 
pomace 
LGG-fermented juice showed improved active ingredients, 
antioxidant and cholesterol clearance capacity, and anti-
fatigue effects in mice
Yan et al., 2019
Yoba probiotic yogurt containing LGG S. thermophilus C106 as used as an adjuvant culture of 
LGG to ferment yogurt; children consuming the yogurt 
showed significant reduction in skin allergies and diarrhea
Kort et al., 2015; 
Westerik et al., 
2018
Orange juice LGG added showed excellent survival in orange juice; 
encapsulated LGG reduced the acidification and negative 
sensory properties of juice
Sohail et al., 2012
Yoghurt containing LGG Combination of fiber-rich rye bread and LGG yoghurt 
improves bowel function in women suffering from 
constipation




Fresh-cut bell pepper The combination of biochemical additives and LGG 
reduced the total counts of bacteria (25.10%), Salmonella 




Fresh-cut pear LGG reduced the L. monocytogenes population by 1.8 logs 
in fresh-cut pear without compromising its quality  
Iglesias et al., 2018
Fresh-cut pear LGG population added on fresh-cut pear remained 
constant in 7-day storage at 10 °C; LGG also reduced the 
resistance of the L. monocytogenes to GI simulation at the 
end of the storage
Iglesias et al., 2017
Others
Edible film Several edible films incorporated with LGG to introduce 
LGG into processed food were developed
Soukoulis et al., 
2017
Oils (canola oil, flaxseed oil etc.) The effects of moisture content and cell conditions on the 
survival of LGG with oils as matrices were evaluated
Endo et al., 2014
While S. boulardii is usually used by oral administration as capsules or pills, in human 
foods the use of S. boulardii has not been largely evaluated. Only few studies have 
investigated the function of S. boulardii in fruit juice and fermented beverage 
(Değirmencioğlu et al., 2016; Fratianni et al., 2014), dairy products (Karaolis et al., 
2013; Lourens-Hattingh and Viljoen, 2001; Parrella et al., 2012), cereals (Heenan et al., 
2004), legumes (Rekha and Vijayalakshmi, 2010) and products derived from them 
(Ryan et al., 2011). In these studies, S. boulardii was not just used as probiotic additive, 
but also acted as a core player to alter the food components and produce bioactive 
substances (Lazo-Vélez et al., 2018). When Rekha and Vijayalakshmi, 2010 used the 
combination of lactic acid bacteria and S. boulardii to ferment soymilk, they observed 
an increase in bioactive isoflavone and mineral bioavailability, and decrease in the 
antinutrient phytic acid. In the black carrot juice fermented by S. boulardii, the final 
concentration of total phenolic compounds was increased, which led to a high 
antioxidant activity (Değirmencioğlu et al., 2016). Ryan et al., 2011 fermented rice bran 
for human use by S. boulardii and an enhanced metabolite diversity after fermentation 
was found. Notably, the extracts from S. boulardii-fermented rice bran inhibited 
lymphoma viability, possibly due to the increased ferulic acid contents compared to 
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nonfermented extracts.
Yeast, due to its ability to metabolize sugars into carbon dioxide and alcohol, is crucial 
in manufacturing alcoholic beverages (Walker and Stewart, 2016). S. cerevisiae is the 
dominant species that is used for the production of beer, wine, whisky, gin and so on. 
Recent research has revealed the close phylogenetic relationship of S. boulardii with S. 
cerevisiae wine strains. Therefore, the use of S. boulardii directly to perform alcoholic 
beverages fermentation holds promise. Osnaya et al., 2017 had determined the growth 
kinetics of S. boulardii in the wort of barley malt. The yeast was found to be well 
adapted, and it was able to hydrolyze the carbohydrates in wort. During recent years, 
scientists have started to put effort on investigating the possibility of using S. boulardii, 
either solely or in combination with S. cerevisiae, to brew “probiotic beer” including 
craft beer (Capece et al., 2018; Mulero-Cerezo et al., 2019; Ramírez-Cota et al., 2021), 
alcohol-free beer (Senkarcinova et al., 2019), and wheat beer (de Paula et al., 2021). 
When applied in combination, S. boulardii did not have negative effects on the beer 
aroma as shown by the analysis of main volatile compounds, and the mixed starter 
increased the antioxidant activity and polyphenols content of the final product (Capece 
et al., 2018). The performance of S. boulardii when applied solely has also been 
evaluated. The viable cell count of S. boulardii in the final product, which matters for 
probiotics, has been found to be maintained at a similar level to S. cerevisiae, i.e., 
8.3×106 CFU/ml and ranged from 8.0×106 to 7.0×106 CFU/ml in the study of Mulero-
Cerezo et al., 2019 and Capece et al., 2018, respectively. Interestingly, Mulero-Cerezo 
et al., 2019 also found a higher antioxidant activity, lower alcohol content, but similar 
sensory attributes in the S. boulardii-fermented beer compared to the S. cerevisiae-
fermented beer. It seems that S. boulardii-fermented beer may have a better health value 
without compromised the flavor. Ramírez-Cota et al., 2021 investigated the ethanol 
tolerance of S. boulardii in beer, and they found S. boulardii could withstand 6%-8% 
(v/v) of ethanol. On the other hand, beer was often used in meat marinating, and studies 
have shown it could reduce the formation of carcinogens in meat during cooking (Melo 
et al., 2008; Viegas et al., 2015; Viegas et al., 2014; Wang et al., 2019).
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Based on the aforementioned studies, it is feasible to produce “probiotic beer” by S. 
boulardii, in this way S. boulardii may display its dual effects as a probiotic and a starter. 
Yet, it still needs more investigations to elaborate the metabolisms of S. boulardii in 
beer and the optimized parameters to proceed beer fermentation.
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2 AIMS OF THE STUDY
The main aims of this doctoral study were to modify and develop the properties of 
probiotic strains Saccharomyces boulardii CNCM I-745 (I, II) and Lacticaseibacillus 
rhamnosus GG (LGG) (III). Detailed aims were as follows:
a) study the possibility of cloning and expressing the gene encoding the Leuconostoc 
bacteriocin leucocin C, using wild-type S. boulardii CNCM I-745 and its CRISPR-Cas9 
modified URA3 auxotrophic derivative as host;
b) utilize leucocin C-secreting S. boulardii to ferment beer and evaluate its efficacy in 
Listeria decontamination in chicken meat;
c) fix the lactose and casein utilization deficiency of LGG, and generate its non-GMO 
derivative which could grow well in milk.
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3 MATERIALS AND METHODS
All the strains and plasmids are listed in Table 4 and Table 5. Experimental methods 
are summarized in Table 6, and details have been elaborated in publications I, II and 
III. Primers and sequences are listed in Table 7.
Table 4. Strains used in this thesis.
Strains Descriptions Source/reference Used in
Escherichia coli DH5α Library EfficiencyTM DH5αTM 
Competent Cells; intermediate host for 
preserving plasmids
Invitrogen, Carlsbad, CA, 
USA
I, II





S. boulardii SAC2 SAA655 carrying pSF-TEF1-TPI1-
Blast (OG539), vector control
This study I (named as 
Sb-vector)
S. boulardii SAC4 SAA655 carrying pSF-TEF1-TPI1-
Blast-lecC for leucocin C expression
This study I (named as 
Sb-LecC), II
S. boulardii SAA940 URA3 auxotrophic strain of S. boulardii 
CNCM I-745 generated by CRISPR-
Cas9
Bagherpour et al., 2018; Prof. 
Vahid Khalaj, Pasteur Institute 
of Iran, Tehran, Iran
II
S. boulardii SAC10 SAA940 carrying pSF-TEF1-URA3, 
vector control
This study II
S. boulardii SAC12 SAA940 carrying pSF-TEF1-URA3-
lecC, used for leucocin C secretion 




Indicator strain, sensitive to leucocin C, 
ATCC 19118
Prof. Martin Loessner, ETH 
Zurich, Switzerland
I, II
L. lactis LAC409 Recombinant L. lactis NZ9000 that 
produces leucocin C
Wan et al., 2013 I, II
L. lactis NCDO 712 L. lactis subsp. cremoris NCDO 712, 
plasmid donor strain, lactose/casein 
positive
Gasson, 1983 III
L. lactis MG1614 Plasmid-cured derivative of L. lactis 
NCDO712, streptomycin and 
rifampicin resistant, used as positive 
control in conjugation
Gasson, 1983 III
LGG Lacticaseibacillus rhamnosus GG, 
ATCC 53103 




LGG that has been conjugated with 
plasmid pLP712 from L. lactis NCDO 
712, lactose/casein positive
This study III
Table 5. Plasmids used in this thesis.
Plasmids Descriptions Source/reference Used in
pSF-TEF1-TPI1-Blast 
(OG539)
E. coli-yeast shuttle vector, 
antibiotic blasticidin S selection
Oxford Genetics, Oxford, UK I
pSF-TEF1-TPI1-Blast-lecC pSF-TEF1-TPI1-Blast plasmid that 
has been inserted with leucocin C 
expression cassette
GenScript, Piscataway, NJ, USA I
pSF-TEF1-URA3 E. coli-yeast shuttle vector, uracil 
selection
Oxford Genetics, Oxford, UK II
pSF-TEF1-URA3-lecC pSF-TEF1-URA3 plasmid that has 
been inserted with leucocin C 
expression cassette
GenScript, Piscataway, NJ, USA II
Table 6. Methods used in this thesis.
Methods Source/reference Used in
Molecular cloning, nucleic acid techniques, 
e.g., PCR, enzymatic modifications, 
electrophoresis
Electroporation
Sambrook et al., 1989; manuals of the 
enzyme supplier
I, II, III
E. coli Zabarovsky and Winberg, 1990 I, II
S. boulardii Kawai et al., 2010 I, II
DNA isolation
E. coli GeneJET Plasmid Miniprep Kit, Thermo
Fischer Scientific
I, II
L. lactis NCDO 712 Anderson and Mckay, 1983; Wan et al., 
2013
III
LGG Anderson and Mckay, 1983; Wan et al., 
2013
III
Lacticaseibacillus rhamnosus LAB49 Anderson and Mckay, 1983; Wan et al., 
2013
III
Ammonium sulfate precipitation Budde et al., 2003; Wan et al., 2013 I, II
Agar well diffusion assay Lehrer et al., 1991 I, II
Tricine-SDS-PAGE Schägger, 2006 I
Glycine-SDS-PAGE Laemmli, 1970 III
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Gel overlay assay Bhunia et al., 1987 I, II
Bacteria broth conjugation McKay et al., 1980 III
Agar halo method for verifying protease 
activity
van den Berg et al., 1993 III
Casein degradation assay Vukotic et al., 2015 III
Growth rate determination Zierdt and Swan, 1981 III
Ethanol analysis by HPLC Mattila et al., 2018 II
Inhibition of L. monocytogenes attached to 
meat
Nielsen et al., 1990 II
Table 7. PCR primers sequences and source.
Primers Sequence 5’ end to 3’ end Reference Size Use
pSF specific-F CATATCACATAGGAAGCAACAG
This study 1400 bp
lecC insertion 
verificationpSF specific-R CTACGATACCGATAGAGATGG
spaC-FW CCAAATTGGCAACAGACCTT de Vos et al., 
2010
801 bp LGG- specific
spaC-RV GCCATCTGGTGCTTTTGTTT
GG-spec-A CGCCCTTAACAGCAGTCTTC Ahlroos and 
Tynkkynen, 
2009
757 bp LGG- specificGG-spec-B GCCCTCCGTATGCTTAAACC
prtP-FW CTCGAGGCTAGCTCGTTTGATTTAATTGTG
This study 2550 bp pLP712 specific
prtP-RV CCAGAATTCGGGCCCTATTCTTCACGTTGTTTCCG
repAC-FW CGTTTCTGAGACGTTTTAGCG
This study 1680 bp pSH71 specific
repAC-RV AAATAAAAGCCCCCTTCGACT
pSH72-FW GCTTTTTCGTTGGTTTGCTC Tarazanova 
et al., 2016
466 bp pSH72 specific
pSH72-RV GCCCAAAATAGTGGGTTAGTG
pSH73-FW TTTCAGTAGAAGGCCAAACAAC Tarazanova 
et al., 2016
803 bp pSH73 specific
pSH73-RV TGCAAATTTATCTACAAAGGCTTG
pSH74-newFW GTGGATGAACAAACAAAATACG
This study 195 bp pSH74 specific
pSH74-newRV GGATTGTGTCGATTTGCTTTACGC
pNZ712-FW CACTCTAGTTTCCTACCTTCGTTGCAAGC Tarazanova 
et al., 2016
1120 bp pNZ712 specific
pNZ712-RV GCTATACTTATACGGAGGATTAGCACTGG
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4 RESULTS AND DISCUSSION
4.1 Heterologous expression of leucocin C in S. boulardii (I, II)
The DNA sequence of the complete leucocin C gene cluster from Ln. carnosum 4010 
has been reported by Wan et al., 2013 (GenBank accession number: JQ061256.3). The 
leucocin C precursor gene has 204 bp nucleotides encoding 67 amino acids, in which 
there is a signal peptide with 24 aa in length. In this present study, the 132 bp gene 
fragment (lecC) encoding the mature peptide of leucocin C was selected to perform the 
molecular cloning in S. boulardii. To guide the extracellular secretion in yeast cells, a 
α-mating factor signal sequence from S. cerevisiae (Brake et al., 1984) was fused before 
lecC (Figure 3).
For heterologous expression of leucocin C in S. boulardii SAA655 (I) and SAA940 (II), 
the vector pSF-TEF1-TPI1-Blast (pSF-Blast) (Figure 3) and pSF-TEF1-URA3 (pSF-
URA3) were used, respectively. These two vectors are both equipped with basic 
plasmid components, e.g., kanamycin-resistant gene (KanR) for bacterial transformants 
selection, constitutive promoter TEF1 (yeast translation elongation factor 1), and 
2Micron replicon (2μ). The difference between the plasmids is that the selection marker 
is dedicated to different yeast hosts. For the purpose of antibiotic selection, blasticidin 
S resistance cassette (Blast) was provided in pSF-Blast used in wild-type S. boulardii 
SAA655. While for uracil selection, URA3 gene encoding orotidine-5'-phosphate 
decarboxylase was provided in pSF-URA3 to allow the growth of the auxotrophic strain 
S. boulardii SAA940 in medium without uracil. Taken pSF-Blast as the example, the 
cloning strategy is shown in Figure 3.
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Figure 3. Cloning of lecC expression cassette into pSF-TEF1-TPI1-Blast. The expression cassette 
containing DNA fragment of lecC and α-mating factor was cloned into in the vector pSF-TEF1-TPI1-
Blast (OG539) at the enzyme sites EcoRI and XbaI. Red arrows indicated the binding sites of plasmid 
specific primers pSF specific-F/R (Table 7).
The probiotic yeast S. boulardii is not typical host for heterologous gene expression, 
since only few genetic tools are developed or examined for S. boulardii. However, S. 
boulardii tolerates heat and acid better than S. cerevisiae (Edwards-Ingram et al., 2007), 
and it can be easily cured from intestine (Klein et al., 1993). These features make S. 
boulardii an ideal vehicle for bioactive molecules delivery. Therefore, the genetic 
manipulation of S. boulardii has become more and more attractive for scientists. We
first used the antibiotic selection system, which is commonly used (Douradinha et al., 
2014; Latorre-García et al., 2008; Michael et al., 2013; Pöhlmann et al., 2013; Wang et 
al., 2014) when the auxotrophic strains of S. boulardii CNCM I-745 are not yet 
available. The constructed strain S. boulardii SAC4 (named as Sb-LecC in publication 
I) secreted the Leuconostoc bacteriocin leucocin C, which actively inhibited the growth 
of L. monocytogenes (Figure 4b; also in publication I, Fig. S2 in supplementary 
materials). This was the first study presenting the secretion of antimicrobial peptides in 
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S. boulardii.
Figure 4. Anti-listerial test. (a) Agar inhibition assay. The overnight culture of yeast was added on 
Listeria indicator plate after washing to indicate the inhibition of Listeria by directly using S. boulardii
SAC4 cells. The cell density of SAC4 culture was 5.1×107 CFU/ml, SAC2 was 5.4×107 CFU/ml, and 
SAA655 was 7.4×107 CFU/ml. An inhibition halo was observed only around SAC4 cell lawn. (b) Agar 
well diffusion assay. Supernatant from SAA655, SAC2, and SAC5 was collected and concentrated by 
ammonium sulfate precipitation. SAA655 sup: 90 μl of the supernatant from wild-type S. boulardii 
CNCM I-745; SAC2 sup: 90 μl of the supernatant from SAC2 strain; PC: positive control, 10 μl of the 
supernatant from the leucocin C producing L. lactis LAC409 strain; SAC4 sup: 90 μl of the supernatant 
from SAC4.
Later we obtained a URA3 auxotrophic strain of S. boulardii CNCM I-745. This strain 
was named as S. boulardii SAA940, and the same cloning strategy was applied to yield 
a S. boulardii SAC12 strain (II). The auxotrophic host SAA940 originated from the 
wild-type strain S. boulardii CNCM I-745, which is the same wild-type strain we used
previously in cloning with antibiotic selection. Therefore, the different behaviors of S. 
SAC4               SAC2           SAA655
a
SAA655 sup        SAC2 sup
      
     PC             SAC4 sup
b
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boulardii under two different selection systems can be compared. As expected, anti-
listerial peptide leucocin C could be secreted by the new constructed strain S. boulardii 
SAC12 (publication II, Fig. 2). Interestingly, we found that the anti-listerial effect of 
leucocin C from SAC12 was much stronger than leucocin C from SAC4 (publication 
II, Fig. 3A). Even though SAC4 and SAC12 grew in different selective media with 
different pattern, both strains could reach stationary phase within 36-h incubation 
(publication II, Fig. 3B). The final cell density of SAC4 and SAC12 was not decided, 
the reason was that we considered the ability to grow in each strain’s selective medium 
also matters when compare the leucocin C-secreting ability. Since the initial cell density 
of SAC4 and SAC12 after inoculation was similar, their leucocin C-secreting ability 
was comparable within the same growth period. Besides the differences in leucocin C 
secretion level, antibiotic blasticidin S selection used for SAC4 strain was expensive 
and not environmentally friendly. The presence of the antibiotic also made the recovery 
of secreted product more complicated, since the antibiotic remained in the yeast 
supernatant. Considering the two important features of URA3 selection system in this 
study: antibiotic free and higher production of leucocin C, it might potentially act as a 
superior gene expression method for S. boulardii CNCM I-745 and expand its usage. 
Based on this consideration, we decided to test the possibility of using SAC12 in beer 
fermentation and use the beer containing leucocin C in food matrix, as higher 
production of leucocin C might help killing more L. monocytogenes (II).
Strictly speaking, the word “probiotics” is not a term based on taxonomy, but refers 
more to functionality. Regarding this topic, O'Toole et al., 2017 proposed an interesting 
idea that “nothing in the definition of the term probiotics limits the species, genus or 
even kingdom from which probiotics can be selected, nor does it dictate whether they 
must be native strains or whether they can have been subjected to any form of genetic 
manipulation.” Therefore, studies about commensals or genetically engineered 
probiotics that could be used as NGPs are emerging. Specifically, engineered probiotic 
microorganisms secreting bacteriocins, for example L. lactis secreting Hiracin JM79 
(Sánchez et al., 2008) and lactococcin A (Chikindas et al., 1995), and 
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Lactiplantibacillus plantarum secreting ABP-118 (Flynn et al., 2002), could be applied 
as a dual therapy to control bacterial infections. Direct antimicrobial effects have not 
been reported for the probiotic yeast S. boulardii, only studies showing its binding to 
some enteric pathogens like Salmonella (Martins et al., 2013), E. coli (Dahan et al., 
2003), and Shigella (Mumy et al., 2008) are available. In our case, we focused on 
improving the probiotic effects of S. boulardii by adding the ability to kill Listeria. 
Expression of leucocin C enabled S. boulardii to directly kill Listeria even without 
selection pressure (publication I, Fig. 3). The engineered leucocin C secreting S. 
boulardii could be developed as a type of NGPs for controlling human listeriosis.
4.2 Beer fermentation by leucocin C-secreting S. boulardii (II)
Our strategy of constructing leucocin C-secreting S. boulardii was successful, 
presenting the first anti-listerial probiotic S. boulardii. Especially, the S. boulardii 
SAC12 secreted more leucocin C than the S. boulardii SAC4, and antibiotic selection 
was not needed. Even though, usually S.cerevisiae is used in beer fermentation instead 
of S. boulardii, the beer fermented by S. boulardii SAC12 had an average ethanol 
contents of 4.3% (v/v). The typical content of ethanol produced by yeast during 
fermentation is 3.5%-5.0% (v/v) (Menz et al., 2009). Thus, using S. boulardii SAC12 
to perform beer fermentation seems to be feasible. More importantly, the beer 
fermented by S. boulardii SAC12 carried anti-listerial effect due to the accumulation of 
the secreted leucocin C in beer (publication II, Fig. 4). When the beer was used in real 
food matrix, it displayed an inhibition of up to 2.2 log units, against the L. 
monocytogenes contaminated in chicken breast strips (publication II, Fig. 6). On the 
other hand, the beer might also be equipped with the probiotic substances secreted by 
S. boulardii as a kind of “probiotic anti-listerial beer”.
4.3 Generation of lactose and protease positive LGG (III)
Genetic manipulation is one way for bringing new features to probiotics, but public 
acceptance of GMOs is low and the regulatory requirements make the process to the 
market slow and expensive (Shew et al., 2018). Therefore, it is preferable to add new 
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properties to probiotics using non-GMO techniques. Conjugation happens naturally in 
the world of microorganisms, and it could be used as an excellent tool if proper features 
are transferred. Based on this consideration, we made such attempt to make the wild-
type LGG lactose and PrtP protease positive by conjugal transfer of the lactose-protease 
plasmid pLP712 from Lactococcus lactis NCDO 712. The key part of conjugation is 
the selection of the expected recipient, because the contact between the donor strain 
and recipient is essential for horizontal gene transfer. Here in our study, we used 
vancomycin to counter select the donor strain from the bacteria mixture and lactose to 
select the transconjugant LGG (publication III, Fig. 2). The presence of the pLP712 
plasmid in the transconjugant was confirmed by PCR (publication III, Fig. 3).
Later we isolated the total DNA from the transconjugant LGG: L. rhamnosus LAB49. 
The transconjugant strain LAB49 also carried several plasmids, while from the wild-
type LGG no plasmids were obtained, only chromosomal DNA (publication III, Fig. 4). 
The explanation was that other plasmids of NCDO 712 were mobilized along with the 
conjugation of pLP712. This phenomenon was also observed in the study of Barry et 
al., 2019, in which the mobilization of non-conjugative plasmids along with the 
conjugative plasmid occurred in all 143 conjugation tests. After confirmation of the 
successful conjugation, the phenotypes associated with pLP712 plasmid were 
characterized. The lactose utilization ability was easily identified by the growth of 
LAB49 on xMRS-lactose-BCP plate (MRS without glucose and meat extract, and 
supplemented with 1% lactose, 100 mg/ml vancomycin, and 50 mg/ml bromocresol 
purple) (publication III, Fig. 2), and the proteolytic activity of LAB49 was 
demonstrated by its degradation of β-casein on SDS-PAGE (publication III, Fig. 7). As 
LAB49 was equipped with these two new features, we tested if LAB49 could grow 
better than LGG in milk. LAB49 and LGG were inoculated separately into milk and 
incubated at 37 °C for 36 h. The final cell density is presented in Figure 5. The results 
showed that the transconjugant LAB49 reached 43-fold higher CFU/ml, than the 
parental strain LGG (p<0.05) after 36-h growth in milk. While for LGG, a slight growth 
was observed from 6.35×106 CFU/ml to 5.28×107 CFU/ml. The slight growth was also 
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found when LGG was cultured in xMRS-lactose medium, which means that LGG can 
grow, although poorly, in this medium with lactose as the main carbon source. In 
addition, only LAB49 coagulated the milk, whereas LGG-milk was still liquid after 36 
h at 37 °C (unpublished).
Figure 5. Growth of LAB49 and LGG in milk. The starting cell density inoculated in milk of LGG 
was 6.35×106 CFU/ml, and LAB49 was 7.4×106 CFU/ml. The final cell densities of LGG and LAB49 
were 5.28×107 CFU/ml and 2.28×109 CFU/ml, respectively. Error bars show calculated standard errors 
of the means, * represents the significant difference between the CFU/ml of each group (P<0.05). 
The growth efficiency of LAB49 in milk was also investigated (III). A growth curve of 
time versus CFU/ml of LAB49 was generated to demonstrate its better growth 
efficiency (publication III, Fig. 8) than wild-type LGG. However, before LAB49 could 
display such a “normal” growth profile, it actually needed to be activated for 20 h in 
milk. When LAB49 was directly inoculated from medium into milk, it still needed a 
long lag phase before entering a rapid growth (Figure 6). Such phenomenon might be 
caused by the time needed to activate the transcription of lac gene cluster or prtMP 
genes, which was introduced externally into LAB49. The induction of carbohydrate 
metabolism when the cells encounter different sugar sources is common in LAB (Afzal 
et al., 2014; Gosalbes et al., 2001; Tsai and Lin, 2006). Another reason might be the 























LAB49 produced PrtP, it takes some time before the enzyme has digested casein, 
followed by intake of peptide fragments and activity of peptidases to release free amino 
acids for growth.
Figure 6. Growth of LAB49 and LGG that are directly inoculated from medium into milk. The 
starting cell densities of LGG and LAB49 were 5.0×106 CFU/ml and 6.31×106 CFU/ml, respectively. 
Both strains grew slightly during the first 12 hours, after which LAB49 started rapid growth until 24 h. 
LGG maintained low growth during the 36-h incubation. Error bars show calculated standard errors of 
the mean.
Compared to wild-type LGG, the lactose and casein positive Lacticaseibacillus 
rhamnosus LAB49 could exert new functions in dairy applications, such as, alleviating 
the symptoms of lactose intolerance or CMPA. Even though wild-type LGG has been 
reported to function in CMPA by mediating the gut immune response and thereby
boosting the host tolerance (Scalabrin et al., 2017), it would still be interesting to test 
the efficacy of LAB49 as it directly hydrolyzes casein and might reduce more 





















5 CONCLUSIONS AND FUTURE PROSPECTS
In this thesis, the main aim was to explore ways of modifying probiotic strains S. 
boulardii CNCM-I715 and LGG, and thereby develop their benefits or usage. 
Regarding S. boulardii, the genetic tools and selection systems we used were 
demonstrated to be valid in expressing heterogeneous genes in this probiotic yeast. The 
introduced lecC gene enabled the secretion of Leuconostoc bacteriocin leucocin C in S. 
boulardii, and the recombinant strain displayed sufficient capability to kill foodborne 
pathogen L. monocytogenes without selection pressure. One usage of the leucocin C 
secreting S. boulardii was to ferment “probiotic anti-listerial beer”, which could help 
with excluding L. monocytogenes from contaminated meats upon marination. Here in 
this thesis, we demonstrated such possibility and thus the “probiotic anti-listerial beer” 
might be equipped with the dual effects of anti-listeria activity and probiotic benefits 
of the engineered S. boulardii. Another usage in the future is to test the in vivo efficacy 
of leucocin C secreting S. boulardii in mice model, and apply as a type of “next 
generation probiotic” or “live biotherapeutic product” aiming to deliver leucocin C into 
gastrointestinal tract and control Listeria infection.
As for LGG, a probiotic bacterium that is commercially used in food, a non-GMO 
derivative strain LAB49 was generated by bacterial conjugation. The strategy of 
applying L. lactis NCDO712 as donor strain made it possible to fix the deficiency of 
lactose and casein utilization of LGG. Even though the transfer frequency was low, with 
proper screening method it was possible to identify the transconjugants. The utilization 
of lactose and casein of LAB49 was verified at both gene and phenotype level and most 
importantly it grew better in milk than the wild-type LGG. Therefore, the L. rhamnosus 
LAB49 can be regarded as an upgraded food-grade and non-GMO derivative of LGG. 
Since the conjugated plasmid has provided new properties to LAB49 compared to LGG, 
it may raise a concern about the probiotic capacity of LAB49. In the further studies, it 
would be good to investigate whether LAB49 still holds the probiotic activity of LGG, 
e.g., the adherence to epithelial cells. Moreover, the possibility of applying LAB49 in 
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fermenting “probiotic yogurt” and its benefits in reducing symptoms of lactose 
intolerance and CMPA would also be interesting to test in vivo.
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Thanks for everything! Kiitos! !
Ran Li
September 2021     Helsinki, Finland
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